title: High density lipoprotein apolipoprotein AI kinetics in NIDDM: a stable isotope study.
abstract: High density lipoprotein (HDL) kinetics were studied by infusing [5,5,5-2H3]-leucine in five subjects with normal glucose tolerance and eight patients with non-insulin-dependent diabetes mellitus (NIDDM) with poor metabolic control (HbA1c = 8.16 +/- 1.93%) (mean +/- SD). HDL were modelled as a single compartment since no kinetic differences were observed between HDL2 and HDL3 subclasses. Plasma apolipoprotein AI (apo AI) concentration was significantly lower in NIDDM patients (96.1 +/- 12.1 vs 124.4 +/- 13.1 mg.dl-1, p < 0.01). HDL composition was altered in NIDDM, as an increase in HDL-triglyceride and a decrease in HDL-cholesterol, negatively correlated (r = 0.780, p < 0.01). The mean fractional catabolic rate (FCR) of apo AI-HDL was significantly higher (0.39 +/- 0.16 vs 0.21 +/- 0.06 d-1, p < 0.05) while the apo AI-HDL absolute production rate was not significantly greater (13.6 +/- 5.1 vs 12.0 +/- 4.2 mg.kg-1.d-1) in diabetic patients compared to normal subjects. There were significant correlations between apo AI-HDL FCR and plasma apo AI concentration (r = -0.580, p < 0.05), plasma triglycerides (r = 0.839, p < 0.0001) or HDL-triglyceride levels (r = 0.597, p < 0.05). No correlation was observed between apo AI-HDL FCR and HbA1c or HDL-cholesterol level. These data support the view that the decrease in plasma apo AI level in patients with NIDDM is due to an increase of apo AI-HDL FCR, which may itself be related to changes in HDL composition.
authors.affiliation: Center de Recherche en Nutrition Humaine, Hôpital G. & R. Laënnec, Nantes, France.
authors.forename: R
authors.initials: R
authors.lastname: Frénais
authors.forename: K
authors.initials: K
authors.lastname: Ouguerram
authors.forename: C
authors.initials: C
authors.lastname: Maugeais
authors.forename: P
authors.initials: P
authors.lastname: Mahot
authors.forename: P
authors.initials: P
authors.lastname: Maugère
authors.forename: M
authors.initials: M
authors.lastname: Krempf
authors.forename: T
authors.initials: T
authors.lastname: Magot
mesh_terms: D000328:Adult; D016632:Apolipoprotein A-I / Q000096:biosynthesis / Q000097:blood*; D001786:Blood Glucose / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood; D003903:Deuterium; D003924:Diabetes Mellitus, Type 2 / Q000097:blood*; D005260:Female; D005951:Glucose Tolerance Test; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007700:Kinetics; D007930:Leucine / Q000378:metabolism; D008075:Lipoproteins, HDL / Q000097:blood; D008297:Male; D008875:Middle Aged; D011865:Radioisotope Dilution Technique; D012016:Reference Values; D014280:Triglycerides / Q000097:blood
chemical_list: D016632:Apolipoprotein A-I; D001786:Blood Glucose; D002784:Cholesterol; D008076:Cholesterol, HDL; D003903:Deuterium; D006442:Glycated Hemoglobin; D007930:Leucine; D008075:Lipoproteins, HDL; D014280:Triglycerides; C034396:HDL-triglyceride